RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+12%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.07B
AUM Growth
+$3.07B
(-7.2%)
Cap. Flow
-$383M
Cap. Flow
% of AUM
-12.45%
Top 10 Holdings %
Top 10 Hldgs %
34.44%
Holding
116
New
6
Increased
34
Reduced
30
Closed
6
Top Buys
| 1 |
Summit Therapeutics
SMMT
|
$22.8M |
| 2 |
Eli Lilly
LLY
|
$18.2M |
| 3 |
Nuvalent
NUVL
|
$17.8M |
| 4 |
ZBIO
Zenas BioPharma, Inc. Common Stock
ZBIO
|
$14.9M |
| 5 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$11.4M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$156M |
| 2 |
Idexx Laboratories
IDXX
|
$58.2M |
| 3 |
Evolent Health
EVH
|
$56.8M |
| 4 |
Boston Scientific
BSX
|
$30M |
| 5 |
Acadia Healthcare
ACHC
|
$23M |
Sector Composition
| 1 | Healthcare | 97.81% |
| 2 | Consumer Staples | 1.99% |
| 3 | Industrials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
INZY
51
DELISTED
Inozyme Pharma
INZY
| $19.9M | 0.65% |
3,802,883
+104,509
| +3% | +$547K |
|
52
Vera Therapeutics
VERA
$1.47B
| $17M | 0.55% |
383,492
+2,300
| +0.6% | +$102K |
|
53
Dyne Therapeutics
DYN
$1.92B
| $16.6M | 0.54% |
461,028
| – | – |
|
54
Novo Nordisk
NVO
$252B
| $15.7M | 0.51% |
132,000
-15,500
| -11% | -$1.85M |
|
|
ZBIO
55
Zenas BioPharma, Inc. Common Stock
ZBIO
$722M
| $14.9M | 0.48% |
+878,667
| New | +$14.9M |
|
56
Applied Therapeutics
APLT
$73.7M
| $14.8M | 0.48% |
1,746,449
+191,445
| +12% | +$1.63M |
|
57
Crinetics Pharmaceuticals
CRNX
$3.26B
| $14.8M | 0.48% |
289,400
| – | – |
|
58
Pharvaris
PHVS
$1.41B
| $14M | 0.46% |
756,931
| – | – |
|
59
Amicus Therapeutics
FOLD
$2.42B
| $13.4M | 0.43% |
1,250,280
+31,700
| +3% | +$339K |
|
60
Johnson & Johnson
JNJ
$429B
| $13M | 0.42% |
80,000
-90,000
| -53% | -$14.6M |
|
61
Cullinan Oncology
CGEM
$456M
| $12.3M | 0.4% |
736,914
+78,576
| +12% | +$1.32M |
|
|
BCAX
62
Bicara Therapeutics Inc. Common Stock
BCAX
$655M
| $11.4M | 0.37% |
+445,975
| New | +$11.4M |
|
63
Enliven Therapeutics
ELVN
$1.24B
| $10.9M | 0.36% |
428,571
| – | – |
|
64
Neumora Therapeutics
NMRA
$283M
| $10.9M | 0.36% |
828,101
+68,094
| +9% | +$900K |
|
65
Cytokinetics
CYTK
$5.98B
| $10.9M | 0.35% |
+206,108
| New | +$10.9M |
|
66
BioMarin Pharmaceuticals
BMRN
$11.3B
| $10.6M | 0.35% |
151,000
| – | – |
|
67
Prothena Corp
PRTA
$452M
| $10.5M | 0.34% |
625,048
| – | – |
|
68
Compass Therapeutics
CMPX
$466M
| $10.4M | 0.34% |
5,629,239
+115,451
| +2% | +$212K |
|
69
Krystal Biotech
KRYS
$4.35B
| $10.2M | 0.33% |
55,861
-49,708
| -47% | -$9.05M |
|
70
Aurinia Pharmaceuticals
AUPH
$1.58B
| $8.65M | 0.28% |
1,179,740
| – | – |
|
71
Jasper Therapeutics
JSPR
$44.2M
| $8.64M | 0.28% |
459,088
+54,753
| +14% | +$1.03M |
|
72
Novavax
NVAX
$1.2B
| $8.21M | 0.27% |
650,000
-25,000
| -4% | -$316K |
|
73
Xencor
XNCR
$594M
| $8.06M | 0.26% |
+401,013
| New | +$8.06M |
|
|
NVRO
74
DELISTED
NEVRO CORP.
NVRO
| $7.72M | 0.25% |
1,381,500
| – | – |
|
75
Dynavax Technologies
DVAX
$1.19B
| $6.74M | 0.22% |
605,013
-687,624
| -53% | -$7.66M |
|